Why I’m Starting this Cholesterol Drug (For My Brain)

Key scientific concepts and mechanisms

Ezetimibe mechanism

• Ezetimibe (Zetia) blocks the intestinal cholesterol transporter NPC1L1, reducing dietary cholesterol absorption and prompting the liver to clear more LDL.
• Unlike statins, ezetimibe acts in the gut and does not inhibit cholesterol synthesis.

Alzheimer’s pathology highlighted

• Protein misfolding and aggregation (amyloid‑beta plaques and tau tangles) drive neuronal dysfunction and death.
• A specific protein–protein interaction implicated in the report: 14‑3‑3 proteins binding hexokinase. Hexokinase normally associates with mitochondria; pathological 14‑3‑3–hexokinase interactions can promote downstream protein aggregation and neuronal dysfunction.

Autophagy

• Autophagy is the cellular “recycling” pathway that clears damaged proteins and organelles.
• Impaired autophagy is a hallmark of Alzheimer’s disease.

Main discovery reported

• An unbiased (hypothesis‑naive) screen of FDA‑approved drugs identified six compounds that disrupt the 14‑3‑3–hexokinase interaction; ezetimibe was one of the hits.
• Ezetimibe was selected for follow‑up because it crosses the blood–brain barrier and has a favorable safety profile relative to many alternatives.

Experimental findings reported:

• In human cell lines, ezetimibe reduced amyloid‑beta and tau accumulation in vitro.
• Ezetimibe increased autophagy by roughly 40% in the assays reported.
• In C. elegans models with fluorescently labeled amyloid, ezetimibe reduced in vivo amyloid accumulation.
• In a retrospective human database analysis (observational), 4,361 ezetimibe users were compared with ~945,000 age‑matched controls; incidence of Alzheimer’s disease and related dementias was reported to be about eightfold lower among ezetimibe users.

Authors’ quoted conclusion (from the video):

Findings suggest ezetimibe “confers a highly significant protection from Alzheimer’s disease and related dementias in individuals with or without coronary disease,” though mechanisms need further study.

Methods / evidence used

• Hypothesis‑naive screen of FDA‑approved compounds targeting the 14‑3‑3–hexokinase interaction.
• In vitro experiments in human cell lines measuring:
  • Amyloid‑beta accumulation
  • Tau accumulation
  • Autophagy markers (reported ≈ +40%)
• In vivo experiments in C. elegans amyloid reporter models.
• Retrospective human database analysis comparing dementia incidence in ezetimibe users versus nonusers.

Quantitative results highlighted

• Autophagy: approximately +40% in the reported assays.
• Observational association: roughly an eightfold lower incidence of Alzheimer’s disease/related dementias among ezetimibe users in the analyzed dataset (4,361 users vs ~945,000 controls).

Caveats and limitations

• No randomized controlled trial (RCT) evidence that ezetimibe prevents Alzheimer’s—this work combined in vitro, worm models and retrospective human data only.
• Retrospective observational findings are prone to confounding and bias; large reported effect sizes require cautious interpretation and independent replication.
• Model limitations: human cell lines and C. elegans may not translate directly to human clinical outcomes.
• The authors and presenter call for further research; a definitive RCT of ezetimibe monotherapy for Alzheimer’s prevention may be unlikely.

Safety and practical considerations

• Ezetimibe is generally considered benign compared with statins (not linked to insulin resistance, diabetes, liver injury, or muscle damage in the presenter’s description).
• Common side effect: gastrointestinal upset, notably diarrhea in a minority of users (presenter reported personal experience).
• Presenter’s personal trial strategy (presented as personal practice, not medical advice):
  • Start low (5 mg), take in the evening with food.
  • Pause or reduce magnesium supplements to reduce diarrhea risk.
  • Stop if side effects are intolerable; consider up‑titration only if tolerated.

Other related points and recommendations mentioned

• Presenter’s other brain‑health measures: low‑dose lithium orotate (5 mg daily), a specific LPC‑DHA omega‑3 formulation (referred to as “centrate Omega Max”), and consideration of NAD boosters (nicotinamide riboside or nicotinamide mononucleotide) after about age 40.
• A new generation CETP inhibitor was referenced (subtitle: “Obeteratib,” likely obicetrapib), noted as relevant to Alzheimer’s and having completed phase 3 trials.

Bottom line / takeaways

• A drug‑repurposing screen identified ezetimibe as a disruptor of a protein interaction implicated in neurodegeneration; ezetimibe reduced amyloid/tau in cell and worm models and increased autophagy, and one retrospective database showed a large association with lower dementia incidence.
• The findings are provocative and biologically plausible but are not definitive proof of prevention. Replication and prospective clinical trials (or stronger human evidence) are needed before changing clinical practice.
• Ezetimibe has a generally favorable safety profile, but gastrointestinal intolerance (diarrhea) can occur. Any decision about use should be made with a clinician.

Researchers / sources featured

• Study reported in the journal described as “Aging Biology” (study authors not named in subtitles).
• Work included: an unbiased FDA‑approved drug screen, human cell line experiments, C. elegans amyloid models, and a retrospective clinical database analysis (cohort sizes reported: 4,361 ezetimibe users vs ~945,000 controls; specific database not named).
• Drugs and molecular players mentioned: ezetimibe (Zetia), statins, PCSK9 inhibitors, a CETP inhibitor (subtitle: “Obeteratib” — likely obicetrapib); NPC1L1 transporter; 14‑3‑3 proteins; hexokinase; amyloid‑beta; tau.
• Presenter disclosures/sources: presenter stated they are an APOE4 homozygote and referenced a newsletter/Substack and other content for deeper dives.